ABINGWORTH
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciences sectors. Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions.
ABINGWORTH
Industry:
Biotechnology Health Diagnostics Medical Medical Device
Founded:
1973-01-01
Status:
Active
Contact:
(207) 534-1500
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Domain Not Resolving Mobile Non Scaleable Content Microsoft Exchange Online Amazon Office 365 Mail
Similar Organizations
Exabone
Exabone GmbH is a Swiss biotechnology leader strategically based within the fast growing life science cluster of Western Switzerland.
Nara Capital
Nara is a purpose-driven investment firm that invests in biotech & life sciences SMEs and startups.
RA Capital Management
RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.
Xip
Xip produces disposable blood analyzers that wirelessly upload lab-quality clinical measurements in minutes.
xRapid
xRapid is a mobile health diagnosis through disruptive solutions leveraging the use of artificial intelligence.
Current Advisors List
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-04-04 | Venatorx Pharmaceuticals | Abingworth investment in Series C - Venatorx Pharmaceuticals | 34 M USD |
| 2021-09-27 | Jasper Therapeutics | Abingworth investment in Post-IPO Equity - Jasper Therapeutics | 100 M USD |
| 2021-09-15 | Anjarium Biosciences | Abingworth investment in Series A - Anjarium Biosciences | 55.5 M CHF |
| 2021-09-08 | HilleVax | Abingworth investment in Venture Round - HilleVax | 135 M USD |
| 2021-08-26 | Effector Therapeutics | Abingworth investment in Post-IPO Equity - Effector Therapeutics | 60 M USD |
| 2021-08-02 | CymaBay Therapeutics | Abingworth investment in Post-IPO Debt - CymaBay Therapeutics | 100 M USD |
| 2021-07-15 | Wugen | Abingworth investment in Series B - Wugen | 172 M USD |
| 2021-06-23 | Glycomine | Abingworth investment in Series B - Glycomine | 35 M USD |
| 2021-04-19 | Adaptate Biotherapeutics | Abingworth investment in Series A - Adaptate Biotherapeutics | 13 M GBP |
| 2021-03-19 | X4 Pharmaceuticals | Abingworth investment in Post-IPO Equity - X4 Pharmaceuticals | 55 M USD |
Newest Events participated
Participated in The 2014 New England Venture Summit
on 2014-12-10 as sponsor